Scientists create universal nasal spray vaccine that protects against COVID, flu, and pneumonia

For decades, the scientific community has pursued the ambitious goal of a universal vaccine, a single immunization capable of shielding against a vast array of infectious agents. This concept, long considered almost mythical in its complexity and potential, has moved significantly closer to reality with groundbreaking research from Stanford Medicine. A new mouse study, published on February 19 in the esteemed journal Science, details the development of an experimental universal vaccine administered intranasally that has demonstrated broad-spectrum protection against diverse respiratory viruses, bacteria, and even common allergens. This innovative approach promises sustained immunity within the lungs for months, marking a profound step towards revolutionizing global health security.

A Decades-Long Quest Reaches a Critical Juncture

The pursuit of a universal vaccine is rooted in the persistent challenges posed by rapidly evolving pathogens and the limitations of conventional immunization strategies. Since Edward Jenner’s pioneering work with cowpox to prevent smallpox in the late 18th century, vaccination has predominantly relied on "antigen specificity." This classical approach introduces a recognizable fragment of a pathogen, such as the spike protein of SARS-CoV-2 or a hemagglutinin protein of influenza, to prime the immune system for future encounters. While remarkably effective for many diseases, this strategy falters when pathogens mutate their surface structures, rendering previous vaccines less potent or entirely ineffective. This necessitates constant updates, exemplified by annual influenza shots and recurrent COVID-19 booster campaigns, which place a significant logistical and economic burden on healthcare systems worldwide.

The global health landscape is consistently threatened by a dynamic array of respiratory pathogens. Influenza alone causes millions of cases of severe illness and hundreds of thousands of deaths annually, according to the World Health Organization. The COVID-19 pandemic underscored the devastating impact of novel respiratory viruses, leading to over 7 million recorded deaths globally and unprecedented disruption. Beyond viruses, bacterial respiratory infections like pneumonia, often caused by Streptococcus pneumoniae or hospital-acquired pathogens such as Staphylococcus aureus and Acinetobacter baumannii, contribute significantly to morbidity and mortality, particularly in vulnerable populations. Furthermore, chronic respiratory conditions like asthma, frequently triggered by allergens such as house dust mites, affect hundreds of millions globally, highlighting the pervasive nature of respiratory health challenges. The vision of a single vaccine addressing such a wide spectrum of threats has, until now, remained largely in the realm of theoretical possibility.

Unprecedented Scope: Protection Across Viruses, Bacteria, and Allergens

The experimental vaccine, developed by researchers at Stanford Medicine and their collaborators, has showcased an extraordinary breadth of protection in preclinical models. In the reported mouse study, vaccinated animals were effectively shielded from SARS-CoV-2 and other coronaviruses, representing a significant defense against both current and potential future pandemic threats. Beyond viral pathogens, the vaccine also conferred protection against Staphylococcus aureus and Acinetobacter baumannii, two notorious culprits behind challenging hospital-acquired infections, often characterized by antimicrobial resistance. Remarkably, the vaccine’s efficacy extended even to common allergens, specifically house dust mites, a frequent trigger for allergic asthma.

Dr. Bali Pulendran, PhD, the Violetta L. Horton Professor II and professor of microbiology and immunology at Stanford Medicine, and senior author of the study, emphasized the unexpected scope of these findings. "The level of protection across so many diverse respiratory threats exceeded our initial expectations," he stated, reflecting on the study’s profound implications. Dr. Haibo Zhang, PhD, a postdoctoral scholar in Dr. Pulendran’s lab, served as the lead author, underscoring the collaborative effort behind this breakthrough. If these promising results can be replicated in human trials, a single intranasal vaccine could dramatically simplify immunization schedules, potentially replacing multiple yearly shots for seasonal respiratory illnesses and offering rapid, broad-spectrum defense against emergent pandemic viruses.

The Limitations of Traditional Vaccinology: An Evolving Challenge

The prevailing paradigm of vaccination, effective for over two centuries, operates on the principle of antigen specificity. Vaccines present the immune system with a unique molecular signature of a pathogen, typically a protein fragment, enabling the body to develop targeted antibodies and T-cells that can swiftly neutralize the real threat upon subsequent exposure. This "lock-and-key" mechanism forms the bedrock of protection against diseases like measles, polio, and tetanus.

However, many pathogens, particularly RNA viruses like influenza and coronaviruses, possess high mutation rates. These mutations can alter the surface antigens that vaccines target, allowing the pathogen to evade previously acquired immunity—a phenomenon known as antigenic drift or shift. "That’s been the paradigm of vaccinology for the last 230 years," Pulendran noted, highlighting the historical reliance on this method. "The challenge is that many pathogens evolve quickly. When viruses change the structures on their surface, previously effective vaccines may lose potency. That is why updated COVID-19 boosters and annual flu shots are necessary."

Most efforts to create broader vaccines have focused on identifying highly conserved regions within viral families, targeting components that mutate less frequently to offer protection across related strains. However, the idea of a single vaccine capable of defending against entirely unrelated pathogens—viruses, bacteria, and allergens—has largely been dismissed as unfeasible. "We were interested in this idea because it sounded a bit outrageous," Pulendran admitted. "I think nobody was seriously entertaining that something like this could ever be possible." This sentiment underscores the revolutionary nature of the Stanford team’s current findings.

A Novel Immunological Strategy: Bridging Innate and Adaptive Defenses

The Stanford experimental vaccine departs fundamentally from traditional antigen-specific approaches. Rather than mimicking a specific viral or bacterial component, this new vaccine is designed to emulate the complex communication signals exchanged between immune cells during an infection. By doing so, it orchestrates a coordinated and more durable response from the body’s two primary defense systems: innate and adaptive immunity.

Conventional vaccines primarily stimulate the adaptive immune system, which is responsible for generating pathogen-specific antibodies and specialized T cells. This system is characterized by its memory, allowing for a rapid and potent response upon re-exposure to the same pathogen, often conferring protection for years. In contrast, the innate immune system is the body’s first line of defense, responding within minutes of infection. It deploys a diverse arsenal of cells, including dendritic cells, neutrophils, and macrophages, which broadly recognize and attack perceived threats without prior exposure. However, innate immune responses are typically short-lived, fading within days.

Pulendran’s team recognized the inherent versatility of the innate system. "What’s remarkable about the innate system is that it can protect against a broad range of different microbes," he explained. The challenge lay in extending this broad, but transient, protection.

The Blueprint from BCG: A Foundation for Innovation

Hints that innate immunity could persist longer than traditionally understood emerged from observations surrounding the Bacillus Calmette-Guerin (BCG) vaccine, a live attenuated strain of Mycobacterium bovis used globally against tuberculosis. Administered to approximately 100 million newborns annually, BCG has shown intriguing "non-specific protective effects," with some studies suggesting it can lower infant mortality from other infections, implying extended cross-protection. However, the precise immunological mechanism behind this phenomenon remained elusive and results sometimes varied.

In 2023, Pulendran’s group published a pivotal study that clarified how BCG mediated its cross-protective effects in mice. They discovered that the tuberculosis vaccine triggered both innate and adaptive immune responses, but uniquely, the innate response remained active for several months. The key finding was that T cells, recruited to the lungs as part of the adaptive response, were actively sending signals that kept innate immune cells in a heightened state of activation. "Those T cells were providing a critical signal to keep the activation of the innate system, which typically lasts for a few days or a week, but in this case, it could last for three months," Pulendran elaborated.

Crucially, as long as this heightened innate activity persisted, the mice exhibited protection against SARS-CoV-2 and other coronaviruses. The team identified these T cell signals as specific cytokines that activate pathogen-sensing receptors, known as toll-like receptors (TLRs), on innate immune cells. This discovery provided a blueprint. "In that paper, we speculated that since we now know how the tuberculosis vaccine is mediating its cross-protective effects, it would be possible to make a synthetic vaccine, perhaps a nasal spray, that has the right combination of toll-like receptor stimuli and some antigen to get the T cells into the lungs," Pulendran stated. "Fast forward two and a half years and we’ve shown that exactly what we had speculated is feasible in mice."

How the Nasal Vaccine Works: Sustained Innate Immunity

The new formulation, designated GLA-3M-052-LS+OVA, is engineered to precisely replicate the T cell signals that stimulate innate immune cells in the lungs. It incorporates specific agonists for toll-like receptors, effectively mimicking the danger signals that typically trigger an immune response. Crucially, the vaccine also includes a harmless "decoy" antigen, ovalbumin (OVA), a common egg protein. This OVA component plays a strategic role: it attracts T cells into the lungs, where they can then provide the sustained cytokine signals necessary to maintain the boosted innate immune response for weeks to months.

In the preclinical study, mice received the vaccine as droplets administered intranasally. Some animals were given multiple doses spaced one week apart. Following vaccination, each mouse was intentionally exposed to a respiratory virus. The results were compelling: with three doses, the vaccinated mice remained protected from SARS-CoV-2 and other coronaviruses for at least three months. Unvaccinated control mice, in stark contrast, experienced severe weight loss, a clear indicator of acute illness, and frequently succumbed to the infections. Their lungs showed extensive inflammation and high viral loads. Vaccinated mice, however, exhibited significantly less weight loss, all survived, and their lungs contained remarkably low levels of virus.

Pulendran characterized the effect as a "double whammy." The sustained innate response acted as a robust initial barrier, reducing viral levels in the lungs by a staggering 700-fold. Any viruses that managed to bypass this formidable first layer of defense were swiftly confronted by a hyper-responsive adaptive immune system. "The lung immune system is so ready and so alert that it can launch the typical adaptive responses—virus-specific T cells and antibodies—in as little as three days, which is an extraordinarily short length of time," Pulendran explained. "Normally, in an unvaccinated mouse, it takes two weeks." This rapid adaptive recall significantly enhances protection and accelerates pathogen clearance.

Beyond Viruses: Efficacy Against Bacterial Pathogens and Allergens

Encouraged by the robust protection observed against viral infections, the research team expanded their investigation to include bacterial respiratory pathogens. They tested the vaccine’s efficacy against Staphylococcus aureus and Acinetobacter baumannii, both notorious for causing severe and often antibiotic-resistant infections, particularly in healthcare settings. The results were equally promising: vaccinated mice were protected from these bacterial infections for approximately three months, mirroring the duration of viral protection.

The team then pondered further applications for lung-specific immunity. "Then we thought, ‘What else could go in the lung?’" Pulendran recounted. "Allergens." To test this innovative hypothesis, mice were exposed to a protein derived from house dust mites, a ubiquitous allergen and a major trigger for allergic asthma globally. Allergic reactions typically involve a specific type of immune response known as a Th2 response, characterized by inflammation and mucus production in the airways. Unvaccinated mice developed a strong Th2 response, leading to significant mucus accumulation in their airways. In stark contrast, vaccinated mice exhibited a much weaker Th2 response and maintained clear, unobstructed airways.

"I think what we have is a universal vaccine against diverse respiratory threats," Pulendran concluded, emphasizing the unprecedented breadth of protection demonstrated across viruses, bacteria, and allergens.

Implications for Global Health Security and Pandemic Preparedness

The development of this universal nasal vaccine carries profound implications for global health security and future pandemic preparedness. The ability to induce broad, long-lasting protection against a multitude of respiratory pathogens with a single administration could dramatically alter the landscape of public health. For instance, a single nasal spray in the fall could potentially replace annual flu shots, COVID-19 boosters, and even provide a degree of protection against common colds and bacterial pneumonia. This streamlined approach would not only reduce vaccine fatigue but also simplify logistics for healthcare providers and public health agencies.

From a pandemic preparedness perspective, a universal vaccine could offer a critical advantage. The rapid emergence of novel pathogens, as seen with SARS-CoV-2, often leaves the world vulnerable while specific vaccines are developed, tested, and manufactured. A pre-emptive universal vaccine could provide an immediate, albeit broad, layer of protection, buying invaluable time for targeted interventions to be deployed. This "first-responder" capability could mitigate the initial surge of infections, reduce healthcare system strain, and save countless lives during the early stages of a novel outbreak.

Moreover, the potential to protect against common hospital-acquired bacterial infections like Staphylococcus aureus and Acinetobacter baumannii is particularly significant in the context of rising antimicrobial resistance (AMR). AMR is a global health crisis, making common infections increasingly difficult to treat and posing a severe threat to modern medicine. By reducing the incidence of these infections, a universal vaccine could indirectly contribute to curbing the spread of resistant strains, lessening the reliance on antibiotics, and preserving the efficacy of existing antimicrobial drugs.

The Road Ahead: From Mouse Study to Human Trials

While the preclinical data from the mouse study are exceptionally promising, the next critical step is to translate these findings into human clinical trials. The initial phase will involve a Phase I safety trial to assess the vaccine’s safety and tolerability in humans. If these results are positive, larger-scale studies would follow, potentially including controlled exposure to infections to evaluate efficacy. Dr. Pulendran optimistically estimates that with adequate funding and successful trials, a universal respiratory vaccine could become available for public use within five to seven years. He projects that for humans, two doses delivered as a nasal spray could be sufficient to confer robust protection.

The potential impact on medical practice would be transformative. "Imagine getting a nasal spray in the fall months that protects you from all respiratory viruses including COVID-19, influenza, respiratory syncytial virus and the common cold, as well as bacterial pneumonia and early spring allergens," Pulendran envisioned. Such a comprehensive and convenient immunization strategy would not only bolster individual health but also significantly reduce the global burden of respiratory illnesses, improve quality of life for allergy sufferers, and enhance the resilience of healthcare systems worldwide.

Addressing the Burden of Respiratory Illnesses and Antimicrobial Resistance

The global burden of respiratory illnesses is immense, encompassing a spectrum from mild common colds to severe pneumonia, which remains a leading cause of death, especially among children and the elderly. The economic costs associated with these illnesses, including healthcare expenditures, lost productivity, and long-term disability, run into hundreds of billions of dollars annually. A universal vaccine capable of mitigating this broad range of threats could lead to substantial public health savings and economic benefits.

Furthermore, the vaccine’s demonstrated efficacy against bacterial pathogens like Staphylococcus aureus and Acinetobacter baumannii presents a powerful new tool in the fight against antimicrobial resistance. These bacteria are often multi-drug resistant, complicating treatment and increasing mortality rates. Preventing these infections through vaccination could reduce the need for antibiotics, thereby slowing the development and spread of resistant strains. This proactive approach is critical in safeguarding the effectiveness of antibiotics for future generations.

This groundbreaking research was a collaborative effort, involving scientists from Emory University School of Medicine, the University of North Carolina at Chapel Hill, Utah State University, and the University of Arizona, underscoring the multidisciplinary nature of such complex scientific endeavors. Funding for this pivotal work was provided by the National Institutes of Health (grant AI167966), the Violetta L. Horton Professor endowment, the Soffer Fund endowment, and Open Philanthropy, highlighting the significant investment and support required to pursue such ambitious and potentially world-changing scientific goals. The journey from a mythical concept to a tangible, promising experimental vaccine reflects the relentless pursuit of innovation in medical science, offering a beacon of hope for a future with significantly reduced respiratory disease burden.